The combination of Mylan and Merck Generics will diversify their product portfolio and broaden their global footprint. In 2006, the combined company would have had revenues of $4.2 billion, EBITDA of approximately $1.0 billion and
approximately 10,000 employees. This will immediately bring the merged entity amongst the top 5 in global generics markets.

Merck Generics is a subsidiary of Merck KGaA, a more than 300-year old global chemical and pharmaceutical conglomerate. Merck Generics has sales in more than 90 countries and is the world's number three ranked generics business by 2006 calendar year revenues. It has more than 400 high quality products.

Mylan Laboratories Inc. is a leading pharmaceutical company with 3 principle subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. Mylan is already a leader in the U.S., and through Matrix Laboratories controls one of the broadest API platforms in the world. Merck Generics provides us with leading positions in many of the world's other key regions. For more information about Mylan, visit http://www.mylan.com.

**********